ATYR - aTyr Pharmaceuticals Analyst Forecast Prices
This chart on the GURU.Markets platform illustrates the price action of aTyr Pharma, Inc. (ATYR), which focuses on developing immunotherapeutic agents. The indicator stands at 14.93. aTyr Pharma, Inc. (ATYR) competes in the niche tRNA synthetase segment against major market players. Primary risks involve a dependence on a limited number of trials and significant capital requirements. Management is currently seeking a strategic ally among industry behemoths to bring its product to market.
Analytical breakdowns for aTyr (ATYR)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Aggregate Debt to Equity aTyr Pharma, Inc.|ATYR - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital aTyr Pharmaceuticals|ATYR - Company Aggregate Debts|Debts to Book Capitalization aTyr|ATYR - Company Long-Term Debt|Company Short-Term Loans and Borrowings aTyr Pharma|Quick Liquidity Indicator atyrpharma.com
- earnings and multiples data:
ATYR - Net Profit|Projected Future Earnings aTyr Pharma, Inc.|ATYR - Price to Earnings Ratio|Future Price to Earnings Multiple aTyr Pharma Inc|ATYR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio aTyr|ATYR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months aTyr Pharma|ATYR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months atyrpharma.com|ATYR - Net earnings per share growth this year|Earnings growth forecast for next year aTyr Pharma, Inc.
General company analysis:ATYR atyrpharma.com
This indicator represents the weighted average of target prices from industry experts, reflecting market expectations for the asset's fair value and the level of acceptable multiples. By analyzing the current consensus valuation, an investor can assess the probability of overpaying for aTyr Pharma (ATYR), whose value currently depends critically not on internal M&A, but on the prospects of securing strategic partnerships with global pharma behemoths.
Competitors of aTyr Pharma, Inc.
Analyst Consensus Forecast argenx.com (ARGX)|BioNTech - Consensus Target|Analyst Forecast Prices ABVX (Abivax SA)|ADMA: Consensus Target|Average Forecast Price Protagonist Corp|Immunovant, Inc. (IMVT) - Price Target Chart|kiniksa.com - Fair Value Consensus|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|KYTX (Kyverna Therapeutics) - Consensus Target|TLSA: Analyst Forecast Prices|Consensus Target CABA|Average Forecast Price Ventyx Biosciences Inc. VTYX|Price Target Chart Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Fair Value Consensus|Eledon Pharmaceuticals - Consensus Target|Fair Value Consensus AGEN|CLYM - Price Target Chart|Forecast Levels Chart ZURA|ADAG: Analyst Consensus Forecast|Ikena Oncology - Fair Value Consensus|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast Equillium Bio|Price Target Chart Connect Biopharma (CNTB)|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Price Target Chart Atara Bio ATRA|IFRX - Consensus Target|X4 Pharmaceuticals - Analyst Consensus Forecast|ACET - Analyst Consensus Forecast|CELU (celularity.com) - Consensus Target|INmune Bio Inc - Fair Value Consensus|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Kezar Life Sciences Inc (KZR) - Analyst Median Target|Price Target Chart SAB Biotherapeutics (SABS)|akaritx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|QTTB - Consensus Target|GOVX: Consensus Target|Analyst Median Target Edesa Biotech Corp EDSA|IBIO: Analyst Consensus Forecast|Carisma Therapeutics Inc. (CARM) - Analyst Consensus Forecast|Consensus Target XTLB|BOLT (Bolt Bio) - Analyst Forecast Prices|Consensus Target HCWB (HCW Biologics Inc.)|APVO - Average Forecast Price|Price Target Chart AIM ImmunoTech AIM|Fair Value Consensus ADTX|GRI - Price Target Chart|Forecast Levels Chart XRTX|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp - Fair Value Consensus|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Analyst Consensus Forecast scinai.com|Price Target Chart CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Fair Value Consensus|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|OCEA (Ocean Biomedical) - Consensus Target|TC BioPharm (Holdings) Plc - Fair Value Consensus|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
